This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Alogliptin oral

Updated 2 Feb 2023 | DPP-4 inhibitors


Tablets containing alogliptin.

Drugs List

  • alogliptin 12.5mg tablets
  • alogliptin 25mg tablets
  • alogliptin 6.25mg tablets
  • VIPIDIA 12.5mg tablets
  • VIPIDIA 25mg tablets
  • VIPIDIA 6.25mg tablets
  • Therapeutic Indications


    Type 2 diabetes (NIDDM) not controlled by diet,weight loss & exercise alone

    Treatment of type 2 diabetes mellitus in combination with other glucose lowering medicinal products including insulin, when these together with diet and exercise, do not provide adequate glycaemic control.



    25mg once daily as add-on therapy to metformin, a thiazolidinedione, a sulfonylurea, or insulin or as triple therapy with metformin and a thiazolidinedione or insulin.

    Patients with Renal Impairment

    Creatinine clearance 30 to 50ml/minute
    12.5mg once daily.

    Creatinine clearance below 30ml/minute or end-stage renal disease requiring dialysis
    6.25mg once daily.

    Alogliptin may be administered without regard to the timing of dialysis. However, experience in such patients is limited.

    Additional Dosage Information

    When alogliptin is used in combination with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycaemia.

    When alogliptin is used in combination with metformin and/or a thiazolidinedione, the dose of metformin and/or the thiazolidinedione should be maintained. However, in case of hypoglycaemia while the patient is treated with triple therapy, a lower dose of metformin or thiazolidinedione may be considered.


    Children under 18 years
    Severe hepatic impairment

    Precautions and Warnings

    History of pancreatitis
    New York Heart Association class III failure
    New York Heart Association class IV failure
    Renal impairment - creatinine clearance below 51ml/minute

    Advise ability to drive/operate machinery may be affected by side effects
    Monitor renal function before treatment and regularly during treatment
    If hepatic impairment symptoms occur monitor LFT & consider discontinuation
    Monitor hepatic function
    Reduce dose in patients with creatinine clearance below 51ml/min
    Advise patients to report symptoms of acute pancreatitis immediately
    Discontinue if pemphigus-type reactions develop
    Discontinue permanently if acute pancreatitis occurs
    Discontinue if pancreatitis is suspected
    Patient to inform DVLA if fitness to drive impaired or hypoglycaemic risk

    Pregnancy and Lactation


    Alogliptin is contraindicated in pregnancy.
    Manufacturers advise to avoid the use of alogliptin during pregnancy as precautionary measure.
    At the time of writing there are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
    Detailed guidance on the treatment of diabetes during pregnancy is available from the National Institute for Health and Clinical Excellence (NICE) at


    Alogliptin is contraindicated in breastfeeding.
    Manufacturers advise either to stop breastfeeding or to discontinue alogliptin therapy.
    At the time of writing, there is no published experience concerning the use of alogliptin during breastfeeding. Animal studies have shown excretion of alogliptin in breast milk. It is unknown whether alogliptin is excreted in human breast milk.

    Side Effects

    Abdominal pain
    Acute pancreatitis
    Anaphylactic reaction
    Bullous pemphigoid
    Erythema multiforme
    Exfoliative dermatitis
    Gastroesophageal reflux disease
    Hepatic failure
    Hepatic impairment
    Hypersensitivity reactions
    Stevens-Johnson syndrome
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2019

    Reference Sources

    Summary of Product Characteristics: Vipidia 6.25mg, 12.5mg, 25mg film coated tablets. Takeda UK Ltd. Revised March 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.